This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

the Dietary Effects of VitaSugar/VitaFiber-IMO in Healthy Adults

This study has been completed.
Alberta Agriculture and Rural Development
Information provided by (Responsible Party):
BioNeutra Inc. Identifier:
First received: October 27, 2011
Last updated: July 24, 2012
Last verified: July 2012
The purpose of this study is to re-confirm the already established health effects and dose tolerance of Isomalto-oligosaccharide or IMO, which is a general health/functional food ingredient.

Condition Intervention Phase
Healthy Other: Isomaltooligosaccharide (digestion-resistant carbohydrates) Other: Sucrose Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Official Title: Double-blind, Randomized, Placebo Controlled Study to Investigate the Dietary Effects of VitaSugar/VitaFiber-IMO in Healthy Adults

Resource links provided by NLM:

Further study details as provided by BioNeutra Inc.:

Primary Outcome Measures:
  • Dose Tolerance [ Time Frame: one year ]
    To Evalaute the dietary effects of two dosages of VitaSugar/VitaFiber-IMO on digestive health in healthy adults.

Secondary Outcome Measures:
  • Effect of IMO on human colon microflora and clinical chemistry [ Time Frame: One year ]
    To evaluate effect of VitaSugar/VitaFiber-IMO on human colon microflora and clinical chemistry, including: Prebiotic effect, Quantitative analysis of fecal samples for SCFA, Analysis of Glucose and insulin level and general clinical chemistry.

Enrollment: 60
Study Start Date: November 2010
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
VitaSugar/VitaFiber-IMO dose-1
A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
Other: Isomaltooligosaccharide (digestion-resistant carbohydrates)
12g/dose; three times a day
Other Names:
  • VitaSugar
  • VitaFiber
VitaSugar/VitaFiber-IMO dose-2
A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
Other: Isomaltooligosaccharide (digestion-resistant carbohydrates)
18g/dose, three times a day
Other Names:
  • VitaSugar
  • VitaFiber
Placebo Comparator: Placebo
A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
Other: Sucrose
12g/dose, three times a day
Other Name: Table top sugar

Detailed Description:

Isomalto-oligosaccharide (IMO) is a mixture of natural resistant carbohydrates consisting of short-chains of glucose molecules. IMO is made by enzymatic conversion of starch and uses as a health food ingredient with health benefits of a low calorie sweetener, prebiotic and dietary fiber. IMO have been ingested by humans for last many centuries as it is naturally found in rice miso, sake and soy sauce. IMO already got approval from FDA (GRAS) and from Health Canada.

There are number of published studies (in humans and animals) regarding the health benefits of IMO as an effective prebiotic, and its role in improving overall human gastric health. Studies also showed that IMO have found to be most tolerable with least adverse effects compared to other short-chain resistant oligosaccharides. Current clinical studies are conducted to verify the above given health benefits in BioNeutra's manufactured VitaSugar/VitaFiber-IMO products which including quantitative analysis of Bifidobacteria spp., Lactic acid bacteria group and clostridium spp. The production of short-chain fatty-acids (SCFA) and effect on blood glucose level are also analyzed in addition to the dose tolerance in term of lower and upper permissible dosage with resultant adverse effects if any are also observed.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
  1. Male or female aged 18 to 65 years
  2. If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).


    Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:

    • Double-barrier method (condoms with spermicide or diaphragm with spermicide)
    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Intrauterine devices
    • Vasectomy of partner
    • Abstinence
  3. Healthy as determined by laboratory results, medical history
  4. Agrees not to change current dietary habits and activity levels during the course of the study
  5. Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  2. Participation in a clinical research trial within 30 days prior to randomization
  3. History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable.
  4. Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg or the use of medication for the treatment of hypertension
  5. Unstable medications (dosage must be stable for 90 days prior to randomization
  6. Clinically significant abnormal laboratory results at screening
  7. History of gastrointestinal disease (appendectomy is acceptable) or diabetes
  8. Use of antibiotics and/or laxatives within 2 months prior to randomization
  9. Use of food or supplements containing probiotics within 2 weeks prior to randomization and during the course of the study
  10. Alcohol or drug abuse in past year
  11. Allergy or sensitivity to test product ingredients
  12. Individuals who are cognitively impaired and/or who are unable to give informed consent
  13. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject Concomitant Medications Subjects will be required to washout for 14 days after taking any food or supplements containing probiotics before they can be randomized if the investigator determines that this will not negatively affect the subject's health. Subjects requiring prescribed medications for any acute or chronic conditions will be not be allowed to participate in this trial. Subjects cannot have used antibiotics or laxatives within the 2 months prior to randomization. Birth control is allowed during the study. Subjects who are currently taking prescribed birth control must agree to maintain their current method and dosing regimen during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01462331

Canada, Ontario
KGK Synergize
London, Ontario, Canada, N6A 5R8
Sponsors and Collaborators
BioNeutra Inc.
Alberta Agriculture and Rural Development
Principal Investigator: Mal Evans, PhD KGK Synergize
  More Information

Responsible Party: BioNeutra Inc. Identifier: NCT01462331     History of Changes
Other Study ID Numbers: 11VBHB
Study First Received: October 27, 2011
Last Updated: July 24, 2012

Keywords provided by BioNeutra Inc.:
Human Consumption
Dose tolerance
Short chain fatty acids
Blood glucose
Dose tolerance and prebiotic effect processed this record on August 21, 2017